about
Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsBreakthrough Hormographiella aspergillata infections arising in neutropenic patients treated empirically with caspofungin.Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.Probing the biology of natural products: molecular editing by diverted total synthesis.Healthcare-associated mucormycosis.Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.Current status of antifungal resistance and its impact on clinical practice.Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho.Anti-Candida activity of 1-18 fragment of the frog skin peptide esculentin-1b: in vitro and in vivo studies in a Caenorhabditis elegans infection model.Tinea incognito Caused by Microsporum gypseum in a Patient with Advanced HIV Infection: A Case Report.Mucormycosis as a rare cause of severe gastrointestinal bleeding after multivisceral transplantation.In vitro efficacy of nisin Z against Candida albicans adhesion and transition following contact with normal human gingival cells.Disseminated infection due to Saksenaea vasiformis secondary to cutaneous mucormycosis.
P2860
Q33696043-A7272B12-D8ED-497A-94AE-822247BA2CFCQ34108585-CCC492C3-1CAD-4D3C-8546-B9B412FC1120Q34487440-0BCFAF20-B537-493C-9F94-CD5FC8C0E563Q35605511-F7E89EA2-8E1A-49D7-B383-A77AE9B10669Q37809500-88812DE8-0CA2-4771-8E3F-F3D5CCE0D2F8Q37976049-A8DAE0E0-4754-4EFA-9F7B-CAF7DA00E47FQ38079194-1A8BF5C9-5B7E-4AE6-836B-AE474F6F0983Q38205859-59CCE54D-009B-43A0-A61C-D8F5B09CF5E8Q39127825-19CDFB5E-A869-4566-B3DF-F6A5C80A1740Q39196802-992CF179-3523-4F90-BFB5-70C455716603Q40016281-6E83AE68-1615-4ED6-BB9C-D781399CC29FQ40055779-D8C2CA78-C877-48BF-975A-80C561782B7AQ42708452-12B4C99C-08F0-4834-8F0E-1FCA46AC87C1Q42713791-E1CF1060-2BA0-4C30-AB9A-148E2B1F0E80Q44809997-C31930C1-E5D6-4C86-B1EF-9EA33B1E0DB3Q45987734-53779DC8-63CB-4AF5-A3EB-232208845E51Q48036764-3C863AD8-3F6F-49F8-9A57-6758B9DE664A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Liposomal amphotericin B: what is its role in 2008?
@en
Liposomal amphotericin B: what is its role in 2008?
@nl
type
label
Liposomal amphotericin B: what is its role in 2008?
@en
Liposomal amphotericin B: what is its role in 2008?
@nl
prefLabel
Liposomal amphotericin B: what is its role in 2008?
@en
Liposomal amphotericin B: what is its role in 2008?
@nl
P1476
Liposomal amphotericin B: what is its role in 2008?
@en
P2093
F Lanternier
O Lortholary
P356
10.1111/J.1469-0691.2008.01984.X
P478
14 Suppl 4
P577
2008-05-01T00:00:00Z